secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2026-06-03T10:02:29+00:00
Accession:  0001628280-26-040024
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys terminates lorundrostat royalties, secures up to $500M debt facility
------------------------------------------------------------------------------

- Amended Tanabe license: $200M one-time payment; royalties eliminated; license perpetual; up to $365M in milestones remain.
- Secured $500M senior secured loan; $100M drawn; further tranches tied to FDA approval and net sales.
- Loan matures 2031; interest SOFR+5.5% (floor 3.25%); secured by all assets including IP.
- Change of control would accelerate $100M new milestone payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/0001628280-26-040024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/mlys-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-040024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer